217
Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury.
Nephrology (Carlton). 2023
doi: 10.1111/nep.14254.PubMed
doi: 10.1111/nep.14254.PubMed
206
Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.
J Am Heart Assoc. 2023PubMed
205
Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients.
Int Urol Nephrol. 2023PubMed
182
Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis.
Tohoku J Exp Med. 2021PubMed
179
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.
J Diabetes Res. 2021
doi: 10.1155/2021/7382620. PubMed
doi: 10.1155/2021/7382620. PubMed
138
Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study.
Diabetol Int. 2018PubMed
136
Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice.
Naunyn Schmiedebergs Arch Pharmacol. 2018PubMed
129
Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucoselowering-independent manner.
BMJ Open Diabetes Res Care. 2017PubMed
126
Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury.
Hypertens Res. 2017PubMed
125
Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression.
Eur J Pharmacol. 2017PubMed
115
The protective effect of human atrial natriuretic peptide on renal damage during cardiac surgery.
J Anesth. 2016PubMed
113
The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients.
Clin Exp Nephrol. 2016PubMed
107
Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.
Cardiovasc Diabetol. 15(1): 76, 2016.PubMed
106
Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury.
Am J Physiol Renal Physiol. 310(11):F1366-1376, 2016.PubMed
96
Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats.
Physiol Rep. 3(12), 2015.PubMed
91
Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.
Scand J Clin Lab Invest. 75(5): 421-427, 2015.PubMed
89
Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment?
Nephrology. 10(4):e0122212, 2015.PubMed
85
Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Clin Exp Nephrol. 19(6): 1044-1053, 2015.PubMed
62
A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.
Am J Physiol Renal Physiol. 305(12): F1796-1803, 2013.PubMed
58
Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
Diabet Med. 29(8): e184-190, 2012.PubMed
56
Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
Hypertens Res. 35(11): 1058-1062, 2012.PubMed
51
Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET).
Internal Medicine. 50(12): 1273-1278, 2011.PubMed
50
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Hypertens Res . 34: 935-941, 2011.PubMed
39
Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.
Am J Med Sci. 339(2): 157-163, 2010.PubMed
38
Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Kidney Blood Press Res. 33(3): 213-220, 2010.PubMed
37
Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.
Eur J Clin Invest. 40(9): 790-796, 2010.PubMed
35
Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury.
Am J Pathol. 174(4): 1203-1211, 2009.PubMed
33
Tubular and glomerular injury in diabetes and the impact of ACE inhibition.
Diabetes Care. 32(9): 1684-1688, 2009.PubMed
26
Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.
Kidney Int. 73(12): 1374-1384, 2008.PubMed
25
Renoprotective effect of telmisartan in patients with chronic kidney disease.
Clin Exp Hypertens. 30(7): 662-672, 2008.PubMed
24
Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.
Clin Nephrol. 70(5): 385-392, 2008.PubMed
21
Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.
Diabetologia. 50(2): 490-492, 2007.PubMed
20
Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Am J Med Sci. 333(6): 321-326, 2007.PubMed
19
Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
Am J Hypertens. 20(11): 1195-1201, 2007.PubMed
15
Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.
Clin Nephrol. 65(1): 1-6, 2006.PubMed
14
Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.
Diabetes Metab Res Rev. 22(5): 385-389, 2006.PubMed
13
Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia.
Am J Nephrol. 26(3): 276-280, 2006.PubMed
12
Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.
Am J Nephrol. 26(1): 82-86, 2006.PubMed
7
Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.
TAm J Med Sci. 330(4): 161-165, 2005.PubMed
6
Effect of Pitavastatin on Urinary Liver-Type Fatty acid-binding Protein Levels in Patients With Early Diabetic Nephropathy.
Diabetes Care. 28(11): 2728-2732, 2005.PubMed